02 Aug Nutra-pharma convergence: the threats and opportunities

This is a fascinating scenario playing out. The pharmaceutical industry is currently experiencing a rather precarious period, often referred to as the “patent cliff”, ie the mass expiry of drugs patents.

As Euromonitor has reported, the situation is further compounded by a...